Gossamer Bio Secures Up to $250M to Fund Seralutinib Through FDA Approval
GOSS sits 41% above its 52-week low of $0.114 on light trading volume (0.3× avg).
Summary
Gossamer Bio announced a structured private placement of up to $250 million, with $150 million committed from institutional investors including EcoR1, RA Capital, and Samsara. The deal includes $25 million at initial closing, $125 million contingent on FDA acceptance of the seralutinib NDA in 2026, and warrants exercisable upon FDA approval for up to $100 million more. This financing follows the company's reacquisition of worldwide seralutinib rights and comes ahead of the planned NDA submission in September 2026. The capital is expected to fund operations into 2028, addressing the going concern warning disclosed in the Q2 10-Q. The committed structure aligns funding with regulatory milestones, reducing near-term dilution risk while providing a clear path to potential approval.
At the time of this announcement, GOSS was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77M. The 52-week trading range was $0.11 to $3.87. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.